Dr. Malcolm A. S. Moore retired from the Memorial Sloan Kettering Cancer Center in 2020. He was the Enid A. Haupt Chair of Cell Biology and researched hematopoietic stem cells and progenitor populations, in normal mice and humans, and in neoplastic and genetic diseases.
Dr. Moore has made many contributions, including discovering granulocyte colony stimulating factor (G-CSF), which can stimulate the production of immune cells. He also led the development of filgrastim, which uses G-CSF to boost numbers of immune cells known as neutrophils. For these accomplishments, he received the 1995 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. Dr. Moore has been a member of CRI’s Scientific Advisory Council since 1990.
It is our hope that future drugs designed to interrupt cancer cells from communicating via nanotubes could help bring us closer to a variety of new treatment options for patients with aggressive cancers.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.